Answers are grounded in this paper and cite their sources.
SARS-CoV-2 Omicron lineage contains variants with multiple sequence mutations relative to the ancestral strain particularly in the viral spike gene. These mutations are associated inter alia with loss of neutralization sensitivity to sera generated by immunization with vaccines targeting ancestral strains or prior infection with circulating (non-Omicron) variants. Here we present a comparison of vaccine formulation elicited cross neutralization responses using two different assay readouts from a subpopulation of a Phase II/III clinical trial.
No takes yet. Share an insight, caveat, or question.
Planas et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: